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There is increasing concern for the potential adverse health effects of human exposures to chemical mixtures. To better understand the com-
plex interactions of chemicals within a mixture, it is essential to develop a research strategy which provides the basis for extrapolating data
from single chemicals to their behavior within the chemical mixture. 1,3-Butadiene (BD) represents an interesting case study in which new
data are emerging that are critical for understanding interspecies differences in carcinogenic/genotoxic response to BD. Knowledge regarding
mechanisms of BD-induced carcinogenicity provides the basis for assessing the potential effects of mixtures containing BD. BD is a multisite
carcinogen in B6C3F1 mice and Sprague-Dawley rats. Mice exhibit high sensitivity relative to the rat to BD-induced tumorigenesis. Since it is
likely that BD requires metabolic activation to mutagenic reactive epoxides that ultimately play a role in carcinogenicity of the chemical, a
quantitative understanding of the balance of activation and inactivation is essential for improving our understanding and assessment of human
risk following exposure to BD and chemical mixtures containing BD. Transgenic mice exposed to 625 ppm BD for 6 hr/day for 5 days exhib-
ited significant mutagenicity in the lung, a target organ for the carcinogenic effect of BD in mice. In vitro studies designed to assess inter-
species differences in the activation of BD and inactivation of BD epoxides reveal that significant differences exist among mice, rats, and
humans. In general, the overall activation/detoxication ratio for BD metabolism was approximately 10-fold higher in mice compared to rats or
humans. A preliminary physiological dosimetry model was developed for BD. The model simulations for the in vitro Vmax and Km for BD oxida-
tion compare favorably with the metabolic rate constants that were determined from the in vitro studies when the in vitro values were
adjusted to account for microsomal content and liver weight in the intact animal. This favorable comparison suggests that in vitro biochemical
parameters derived for BD could be used to predict in vivo metabolism. Using the physiological dosimetry model developed for BD, potential
interactions of BD with other chemicals in the workplace (e.g., BD/styrene), the environment (e.g., BD/benzene), or through certain dietary
influences (e.g., BD/ethanol) were explored. The three examples of simulations of BD chemical mixtures suggest two important general
points regarding chemical interactions. The first relates to extrapolations from high to low doses. Due to the saturable enzyme systems that
metabolize most toxic organic chemicals, it cannot be assumed that the inhibition effects demonstrated at high exposure concentrations will
be proportional, or even significant, at low exposure concentrations. Second, patterns of enzyme induction determined in vitro may not
exhibit the same magnitude of effect in the intact animal. Delivery of the chemical to the site of the enzyme chemical interaction may be, in
some cases, the rate-limiting factor, rather than the quantity of the enzyme present.-Environ Health Perspect Vol 102(Suppl 9):87-94 (1994)
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Introduction
Toxicological Interactions ofChemicals
firom Environmental, Industrial, and
DietaryExposures
There is increasing concern for the potential
adverse health effects of human exposures to
chemical mixtures. As recently as the mid-
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1980s, a symposium was held to address
health and environmental research on com-
plex organic mixtures (1). The symposium
was organized to review the existing state of
knowledge regarding materials derived from
energy-related and industrial activities. One
of the major conclusions from this sympo-
sium was thatwhile there is a "vast amountof
information" regarding chemical mixtures,
"more basic questions still need to be
answered." It was concluded that additional
studies were needed to determine the com-
plex interactions among mixture components
and the basic molecular mechanisms that lead
to toxicologic effects in humans. Additional
data must be brought to bear to reduce the
inherent uncertainties in risk assessments
associatedwith chemical mixtures.
A number of critical questions surface
regarding toxicological interactions of
chemicals from environmental, industrial,
and dietary exposures. For example: Do the
chemical interactions influence the toxico-
kinetics ofeach chemical and, ifso, how is
the "dose" to target tissue influenced?
What is known about the dose-dependence
of the various metabolic pathways and are
the chemicals metabolized via similar
enzymes? Are there qualitative and/or
quantitative differences in metabolism
between laboratory animal species and
humans? What role, if any, does enzyme
induction/inhibition play in toxicity?
Which laboratory animal species is/are
appropriate for human risk assessment?
While these questions by no means address
all the important issues regarding chemical
mixtures, they do raise important points
regarding the influence of chemical mix-
tures on the dosimetry ofchemicals.
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1,3-Butadiene as aCaseStudy
1,3-Butadiene (BD) represents an interest-
ing case study in which new data are
emerging that are critical for understanding
interspecies differences in responses to BD.
Fundamental knowledge regarding mecha-
nisms of BD-induced carcinogenicity pro-
vides the basis for assessing the potential
effects of mixtures containing BD. BD, a
widely used monomer in the production of
synthetic rubber and other resins, exhibits
low acute inhalation toxicity in rodents
[LC50 >120,000 ppm; (2)] and causes sen-
sory irritation in humans at concentrations
of 2000 to 8000 ppm (3). Occupational
exposures to BD can result during produc-
tion, storage, and transport of the chemi-
cal. BD has been detected in cigarette
smoke (4) and automobile exhaust (5) and
is currently listed as one of the 189 haz-
ardous air pollutants in the 1990 Clean Air
ActAmendments (6).
BD induces tumors at multiple organ
sites in B6C3F1 mice and Sprague-Dawley
rats (7-9). In mice, several tissues are tar-
gets for BD carcinogenicity, including
heart, lung, mammary gland, ovary,
forestomach, bone marrow, and liver. An
activated K-ras gene was observed in lung
and liver tumors and lymphomas of
B6C3F1 mice exposed to BD (10). The
striking aspect of BD-induced carcino-
genicity is the high sensitivity of mice to
BD. Tumors were observed in mice at con-
centrations as low as 6.25 ppm and steep
concentration-response curves were evident
for several tumors. The tumor sites in rats
are quite disparate and include the thyroid,
mammary gland, Zymbal gland, uterus,
testis, and pancreas. Rats exhibit a rela-
tively low sensitivity to BD, since tumors
occur at BD concentrations (1000-8000
ppm) nearly three orders of magnitude
higher than in mice.
BD displays mutagenic activity in
Salmonella typhimurium, but only in the
presence of hepatic 9000g supernatant
(11-13), indicating that BD is not muta-
genic but that its metabolites, possibly 1,2-
epoxybut-3-ene (butadiene monoepoxide;
BMO) and/or butadiene diepoxide (BDE),
are responsible for the observed bacterial
mutagenicity. BD is also genotoxic in vivo,
inducing chromosome aberrations and sis-
ter chromatid exchanges in bone marrow
cells and micronucleus formation in periph-
eral blood of male B6C3F1 mice (14,15),
but not in Sprague-Dawley rats (15).
The in vivo disposition and metabolism
ofBD have been reported in B6C3F1 mice
(16,17), Sprague-Dawley rats (16-18),
and in the nonhuman primate Macacafas-
cicularis (19). The data from these studies
indicate that there are significant species
differences in the toxicokinetics of BD and
BMO. Mice appear to metabolize BD to
BMO at greater rates than rats. Three
enzymes appear to play major roles in the
overall metabolism of BD: cytochrome
P450-dependent monooxygenases, epoxide
hydrolases, and glutathione (GSH) S-trans-
ferases. In addition to enzymic reactions,
BD epoxides may nonenzymatically
hydrolyze or conjugate with glutathione
(GSH). Presently, there are insufficient data
that quantitatively describe the contribution
of these various pathways in Sprague-
Dawley rats and B6C3F1 mice, species sus-
ceptible to BD-induced carcinogenesis, or
humans, a species potentially at riskfor BD.
Since one or more ofthe BD epoxides may
play a role in the carcinogenicity of BD, a
quantitative understanding of the balance
of activation (i.e., epoxide formation) and
inactivation (i.e., epoxide hydrolysis or con-
jugation) is essential for improving our
understanding and assessment of human
risk following exposure to BD and chemical
mixtures containing BD.
The present paper reports quantitative
species differences in the oxidation of BD
and BMO by cytochrome P450-dependent
monooxygenases and in the inactivation of
BMO by epoxide hydrolases and glu-
tathione S-transferases using microsomal
and cytosolic preparations of livers and
lungs obtained from Sprague-Dawley rats,
B6C3F1 mice, and humans. In vitro
kinetic constants were used for the devel-
opment of a physiologically based dosime-
try model for BD. In addition, transgenic
mice were used to assess the capacity ofBD
to induce in vivo mutations. The data from
these studies provide a quantitative basis
for our understanding of the relative con-
tributions of the various pathways of BD
metabolism in three animal species, includ-
ing humans, and the role that metabolism
plays in forming mutagenic DNA-reactive
BD metabolites. These data serve as the
basis for improving our understanding of
the toxicological interactions of BD with
chemicals resulting from environmental,
industrial, and dietary exposure.
Materials and Methods
Animals
Male Sprague-Dawley (CD) rats (9-10
weeks) and male B6C3F1 mice (9-10
weeks) were obtained from Charles River
Laboratories (Raleigh, NC). The Muta
Mouse (MM) transgenic strain [BALB/c Y
DBA/2 (CD2F1)] of mice (6 weeks) was
purchased from Hazleton Research
Products, Inc. (Hazelton, PA). The con-
struction of the shuttle vector in X phage
(Xgt 10 lacZ), with the inserted bacterial
target gene for mutagenesis (lacZ) and pro-
duction ofthe transgenic mice, is described
in detail elsewhere (20). All animals were
determined to be free from viral infection
and were acclimated for at least 2 weeks
prior to use. Animals were fed with stan-
dard diet (NIH-07; Zeigler Brothers,
Gardners, PA) and received water ad libi-
tum. They were maintained on a 12-hr
light:dark cycle beginning at 0700 and
housed at 22 ± 2°C and 55 ± 5% relative
humidity.
Preparadon of liverandLung
MicrosomesforMetabolismStudies
Rodents were euthanized by either sodium
pentobarbital or CO2 asphyxiation and the
livers and lungs were excised, frozen in liq-
uid nitrogen, and stored at -80°C. Livers
and lungs were slowly thawed while on ice,
weighed, cut into pieces, and homogenized
with four volumes of isotonic KCI-Tris
buffer with six passes of a Teflon-glass
homogenizer (1100 rpm, Braun). Mi-
crosomes and cytosol were prepared as
described previously (21).
Samples of liver (n = 12) from trauma
victims (Tennessee Donor Services,
Nashville, TN) and samples oflung (n = 5)
removed by surgery from cancer patients
(Tissue Procurement Service, University of
Alabama at Birmingham, Birmingham,
AL) were used in these experiments.
Samples were frozen (-800C) and re-
mained frozen during shipment. Tissues
were slowly thawed on ice, homogenized,
and microsomes and cytosol were isolated
as described previously (21).
Protein content was determined using a
modified micro-Lowry method (22).
Cytochrome P450 content was estimated
spectrophotometrically (23).
Enzyme-catalyzedMetabolism ofBD
andBMO
Experiments were conducted to assess
cytochrome P450-dependent metabolism
ofBD, epoxide hydrolase catalyzed hydrol-
ysis ofBMO, and glutathione S-transferase
catalyzed conjugation of BMO with glu-
tathione. Details of the methods used for
these experiments are reported in Csanaidy
et al. (21). Additionally, non-enzymic rates
ofhydrolysis and conjugation were assessed
as described by Csanady et al. (21). A two-
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compartment model was developed to
describe the reaction of BD and BMO in
reaction vials and to calculate the rate con-
stants for oxidation, hydrolysis, and conju-
gation (21).
Physiologicily Based Phannacokinetic
(PBPK) ModelforBD
A PBPK model describing BD disposition
was adapted from a model for styrene toxi-
cokinetics developed by Ramsey and
Andersen (24). The BD model consisted
of a description of the uptake of BD from
the lungs into the blood, the distribution
of BD in blood to four tissue compart-
ments (liver, fat, a compartment represent-
ing skin and muscle, and a compartment
representing richly perfused tissues such as
intestines, blood, kidney and spleen).
Metabolism of BD to BMO was assumed
to take place in the liver compartment and
to proceed by a Michaelis-Menten, or sat-
urable, pathway. Differential equations
describing mass transfer between compart-
ments were numerically integrated using
the Simusolv simulation language software
(Dow Chemical, Midland, MI).
Parameters incorporated into the model
were of three types: physiological, such as
organ volumes, ventilation rates, and blood
flow to various organ groups, chemical,
such as blood/air, and tissue/blood partition
coefficients, and biochemical parameters
describing BD metabolism (Vm,,, and K4).
The physiological parameters were taken
from the literature and partition coefficients
were determined experimentally in vitro
using methods ofGargas et al. (25).
The in vivo biochemical parameters
were determined by exposing mice or rats
to BD gas in a closed, recirculating system
described previously by Gargas et al. (26).
Animals were placed in a sealed chamber
and different initial amounts of BD gas
were introduced into the chamber. Starting
BD concentrations were approximately
5000, 2000 (3000 mice), 1000, 500, and
50 ppm. In this system, uptake of BD by
the animals is a function of both the solu-
biity ofBD in tissues and the rate atwhich
the animal metabolizes the chemical. After
an initial equilibration period, the decline
ofthe concentration ofBD in the chamber
is a direct reflection ofthe rate at which its
biotransformation occurs. The simulation
model described above was used to model
this system. With the physiological and
chemical parameters set, the magnitude of
the metabolic parameters (Vma_x and Km)
was adjusted until model simulations of
BD concentrations in the closed chamber
reflected the experimentally collected data
as determined byvisual inspection.
EFxperimental DesignforMutageniity
Studies
The mutagenicity experiment utilized three
groups ofanimals with five MM per group.
The BD group was exposed to 625 ppm
BD for 5 consecutive days for 6 hr/day.
This exposure concentration was selected
because previous studies indicated that
exposure ofB6C3F1 mice to 625 ppm BD
for up to 60 weeks resulted in significant
elevation oftumor incidences in a number
oforgans (7,8). The two remaining groups
of animals consisted of air controls that
were housed in chambers similar to those
of the BD-exposed group and a group of
animals administered N-ethyl-N-nitro-
sourea (ENU) at 250 mg/kg (ip injection
dissolved in DMSO) as a positive control.
Animals were housed in individual wire
mesh cages inside a 1-m3 Hinners style
chamber (27). During the six hours of
exposure to air or BD, the animals were
without food but had free access to water.
Airflow in the chamber was maintained
within 10% of 15 air changes per hr.
BD exposure levels in the chamber were
monitored by infrared spectroscopy using a
Foxboro Wilkes Miran IA IR (Norwalk,
CT). BD was generated directly from a liq-
uid/gas storage tank as described by Recio
et al. (28). Relative humidity in the cham-
ber was maintained at 50 ± 10% and tem-
perature was maintained at 22 ± 2°C. The
five control mice were similarly housed in a
second chamber in the same room. They
were exposed to clean air ofthe same tem-
perature, relative humidity, and airflow as
delivered to the BD-exposed animals.
AnimalNecropsyandTissueCollec-
tionforMutagenictyStudies
MM were euthanized by an overdose of
sodium pentobarbital and exsanguinated
by cardiac puncture. The liver and lungs
excised from the animals were immediately
frozen in liquid nitrogen and subsequently
stored frozen at -80°C. Bone marrow was
removed from the tibias and femurs by
rinsing with Dulbecco's phospate-buffered
saline (GIBCO, Grand Island, NY). The
cell suspension was placed in a microcen-
trifuge tube and the bone marrow cells
were pelleted in a microcentrifuge at maxi-
mum speed for 30 to 45 sec. The super-
natant was discarded and the cell pellet was
frozen in liquid nitrogen and stored at -800C
until the DNAwas extracted.
DeterminationoflacZ-Mutant
Frequency
To determine the lacZ- mutant frequency
in bone marrow, lung, and liver tissue sam-
ples, DNA was independently extracted
from each tissue for each animal as
described in Recio et al. (28). The DNA
samples for each animal in the same expo-
sure group (five per each exposure group)
were packaged independently into x phage
(28). After the determination ofthe plaque
forming units (pfu) for each individual
DNA sample, an equal number of pfu
from each individual animal within an
exposure group were combined to deter-
mine the IacZ- mutant frequency.
Therefore, a single IacZ-mutant frequency
was determined for each tissue for each
exposure group. A total of 1 x 105 x phage
plaques were examined from the bone mar-
row samples, while in lung and liver sam-
ples, approximately 5 x 105 X phage
plaques were examined. The number of
IacZ- mutant clear or light blue plaques
were counted and "picked" for confirma-
tion by replating on LB medium with
agarose plus X-gal. The lacZ- mutant fre-
quency was calculated by dividing the total
number of confirmed mutant plaques by
the total phage population analyzed, and
was expressed as lacZ- mutants/105
plaques. The number of observed mutant
plaques within each tissue group was used
to determine statistical significance relative
to the tissues from the air control group,
assuming a Poisson distribution.
Results
MutantFrequencyinDifferentTissues
ofMiceFollowingExposure to BD
The IacZ-mutant frequency in three tissues
of mice exposed to 619 ± 3.2 ppm BD
(mean ± SD) and ENU was determined 14
days following the last exposure. The num-
ber of IacZ- mutant plaques observed and
the lacZ- mutant frequency for each tissue
are shown in Table 1. The background
lacZ-mutant frequency in the tissues exam-
ined from control mice ranged from 2 to 4
mutants/105 plaques. The positive control,
ENU, was mutagenic in all tissues exam-
ined. The lacZ- mutant frequency in the
BD-exposed mice did not show a significant
increase in the bone marrow or liver.
However, there was a significant increase in
mutant frequency in the lungs of exposed
mice (p < 0.001).
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Table 1. LacZ mutant frequency in bone marrow,
lung, and liver samples from 1,3-butadiene-exposed
animals and controls.a
No. Mutant
Mutants Frequency (xl0-5)
Bone marrow
Air control 3 3.0
1,3-Butadiene 2 1.8
ENU-exposed 71 73.1
Lung
Aircontrol 29 4.4
1,3-Butadiene 59 9.1b
ENU-exposed 88 16.2b
Liver
Air control 12 2.4
1,3-Butadiene 18 3.1
ENU-exposed 71 13.0
'BD-exposed mice were exposed to 625 ppm BD (6
hr/day for five consecutive days). Controls were
exposed to air only for the same duration as the BD-
exposed mice. Mice dosed with ENU received a single
ip injection of 250 mg ENU/kg. All mice were killed 14
days after the last inhalation exposure or injection for
mutant frequency analysis (28). bSignificantly greater
(p<0.001) than air control for each tissue by Poisson
analysis of the number of mutant plaques relative to
air controls.
MicrosomalMetabolism ofBD
For the enzyme-mediated reactions using
liver and lung microsomes, both the disap-
pearance ofBD from the gas phase and the
appearance of BMO in the gas phase were
measured. The previously determined para-
meters of BMO metabolism were incorpo-
rated into equations (21) used to describe
the in vitro system. The equations were
then used to estimate the Michaelis-
Menten constants for BD oxidation as
described by Csana'dy et al. (21). The
model was found to describe adequately
both BD disappearance from the head-
space and BMO appearance in the head-
space of reaction vials containing liver
microsomes from all species. The
Michaelis-Menten parameters are listed in
Table 2.
The VMmax for BD oxidation to BMO
for human liver microsomes was about
one-half that observed with B6C3F1
mouse liver microsomes and 2-fold higher
than in rat liver microsomes (Table 2). The
apparent K4 parameters for BD oxidation
in liver microsomes from humans,
Sprague-Dawley rats, and B6C3F1 mice
were similar and ranged from 2 to 5 pM.
There were some striking differences in the
calculated Vmax/Km (29). The calculated
Vmax/Km for BD oxidation in B6C3F1
mouse liver microsomes was 6-fold greater
than for rat and human liver microsomes.
With the exception of mice, lung
microsomes displayed considerably lower
capacity to metabolize BD than did liver
microsomes (Table 2). For example, the
Vmax for BD oxidation in lung microsomes
of humans and rats was similar and about
10 and 4 times lower, respectively, than
measured in liver microsomes of the same
species. Apparent Km parameters for BD
oxidation in lung tissue ofall three species
ranged from 2 to 8 pM. The calculated
Vmax/Km for lung microsomal oxidation of
BD was less than liver microsomal metabo-
lism ofBD for all three species.
Microsomal Metabolism ofBMO
Enzyme-mediated hydrolysis of BMO was
not detected in cytosolic fractions of liver
from any of the species. All 12 of the
human liver microsomal samples were
assessed for their ability to metabolize
BMO using one initial BMO concentra-
tion (100 ppm). The normalized first-order
rate constants for the 12 liver samples,
which varied between 0.020 and 0.068
min' mg protein-1, were then rank-ordered
and three samples (high, median, low activ-
ity) were selected for detailed studies of
BMO kinetics. In all cases, results ofmodel
simulations (21) adequately described the
decline in BMO concentration in the head-
space due to enzymic hydrolysis (data not
shown).
Table2. Kinetic constants forthe oxidation of 1,3-butadiene to butadiene monoepoxide.a
Vmax, nmole/mg protein/min Km, pM Vmax/Kmb
Liver microsome
Humans 1.2 ± 0.6 5.1 ± 2.6 230
B6C3F1 mice 2.6 ± 0.06 2.0 ±0.2 1295
Sprague-Dawley rats 0.6 ± 0.1 3.8 ± 0.2 157
Lung microsomes
Humans 0.15 ±0.04 2.00±0.15 75
B6C3F1 mice 2.31 ± 0.26 5.01 ± 0.67 461
Sprague-Dawley rats 0.16 ± 0.01 7.75 ± 1.86 20.6
aValues are mean ± SD(21). bValues are in units oflnmol.(min-mgprotein.mmol)-l.
Table 3. Kinetic constants forthe hydrolysis of butadi-
ene monoepoxide.a
Liver microsomes Vmaxb Km, mM VmaxIKmc
Humansd
high 58.1 ±4.0 1.65± 0.12 35
median 18.5± 4.1 0.58± 0.15 32
low 9.2±2.2 0.24±0.10 38
B6C3F1 mice 5.8 ± 0.3 1.59 ± 0.03 3.6
Sprague-Dawley 2.5 ± 0.05 0.26 ± 0.01 9.5
rats
aValues are mean ± SD (21). bValues are in units of
nmole/mg protein/min. CValues are in units of
nmole*L.(min.mgprotein.mmole)l . dThree of the 12
human liver samples were used for the kinetic analyses.
Selection of the samples were as described in
"Materials and Methods".
Table 3 shows the Michaelis-Menten
constants for BMO hydrolysis by human,
rat, and mouse liver and lung microsomes.
In the three human liver samples used for
the detailed kinetic experiments, Vmax para-
meters ranged from 9 to 60 nmole/mg pro-
tein/min and apparent Km parameters
ranged from 0.2 to 1.6 mM. In contrast,
Vmax determined from reactions using
rodent liver microsomes was one-halfor less
than that measured in human liver samples.
Apparent Km parameters for B6C3F1 mice
were approximately 7- to 8-fold higher than
the Km parameters observed in rats. A com-
parison of the calculated Vma/Km reveals
some striking differences across species
(Table 3). For example, for the three
human liver samples, calculated Vm./Km
parameters ranged from 32 to 38, whereas
in rodents calculated Vma/Km parameters
ranged from 4 to 10.
Lung microsomal preparations from all
three species showed considerably less
capacity to hydrolyze BMO enzymatically.
This was evidenced by the more rapid
decline in BMO concentration in the head
space of the reaction vials when liver
microsomes were incubated with BMO in
the absence of NADPH compared to lung
microsomes (data not shown). Over the
concentration range investigated, BMO
hydrolysis in lung microsomes was best
described as a first-order process. First-
order rate constants for enzymic hydrolysis
ofBMO ranged from 0.004 to 0.008 min-1
mg protein-1 for human lung microsomes
and 0.001 to 0.002 min-' mg protein-I for
rodent lung microsomes.
Enzymic oxidation of BMO was negli-
gible for rats or humans. In contrast,
mouse liver microsomes quantitatively oxi-
dized BMO to BDE (Vmax = 0.2 nmole/
mg/min; Km = 15.6 pM. This qualitative
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Table 4. Kinetic constants forconjugation of butadi-
ene monoepoxide with glutathione.a
Vmax Km,mM" VmaxlKmc
Liver cytosol
Humansd 45.1 ±5.8 10.4 ± 1.04 4.3
B6C3F1 mice 500 ± 64 35.3 ± 6.2 14
Sprague-Dawley 241 ± 3 13.8 ± 0.3 17
rats
Lung cytosol
Humans e
B6C3F1 mice 273 ± 31 36.5 ± 5.5 7.5
Sprague-Dawley 44.2 ± 12.6 17.4 ± 6.2 2.5
rats
aValues are mean ± standard deviation (21). bValues
are in units of nmole/mg protein/min. cValues are in
units of l nmole(min-mg protein.mmole)-1. dTwo of
the 12 human liver samples were used for kinetic
analyses. Selection of the samples were as described
in Materials and Methods. One of the samples dis-
played Michaelis-Menten kinetics and in the other
sample, the reaction was best described by a second-
order rate constant of (2.56 ± 0.22) x 104 liter/mmole/
min/mg protein (mean ± SD). eReactions were best
described by a kgsh = (2.56 ± 0.22) x 104 I/mmole/min/
mg protein (mean ± SD).
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difference in formation of BDE among
rats, mice, and humans has important
implications for BD-induced toxicity.
Conjugation ofBMOwithGSH
Enzyme-mediated conjugation of GSH
with BMO in human and rodent liver
cytosol and rodent lung cytosol could best
be described by Michaelis-Menten kinetics
(Table 4). The Vmax in B6C3F1 mouse
liver cytosolic fractions was about 2-fold
higher than in rat liver cytosol (Table 4).
Only one of the two human liver samples
analyzed displayed Michaelis-Menten
kinetics and had a Vmax of 1/5 to 1/10 of
that observed in rodents. Mouse liver
cytosolic apparent Km parameters were
about 3-fold higher than of rats and
humans. None of the human lung cytosol
samples displayed Michaelis-Menten reac-
tion kinetics. The calculated Vmax/Km in
rodent liver cytosol was about 4-fold higher
than the calculated Vmax/Km for the 1
human sample.
In dvioMetabolism ofBD
Physiological model simulations for the
disappearance of BD from a closed inhala-
tion chamber compared to experimentally
determined data are shown in Figure 1.
Because of the generally low solubility of
BD in blood and tissues (e.g., blood:air
partition coefficient = 1.3 to 1.5), the early
equilibration phase, in which uptake ofBD
into tissues dominates, is very brief as indi-
cated by the initial portions of the model
simulations for the first 20 min of the
experiment. The Vmax and Km values used
to produce these simulations were 40.7
pmole/kg/hr and 3.7 pmole/l, respectively,
s 6 for rats and 163 pmole/kg/hr and
11.1 pmole/l, respectively, for mice. These
values compare favorably with the meta-
bolic rate constants that were determined
from the in vitro studies with microsomes
"1eRR described earlier, when these in vitrovalues
are adjusted to account for microsomal
content and liver weight in the intact ani-
mal (21). This favorable comparison sug-
,'wa~ gests that in vitro biochemical parameters
derived for BD could be used to predict in
vivometabolism.
5 6
Figure 1. Disappearance of butadiene from closed,
recirculating chambers containing mice (top panel) or
rats (bottom panel) at various starting concentrations
of butadiene. Data points (+) represent samples of the
chamber atmosphere analyzed by gas chromatography.
Lines represent the results of physiological model sim-
ulations of the uptake of butadiene from the chamber
bythe animals.
Simulations ofInteractions ofBDwith
Strene, Benzene, andEthanol
Using the physiological model developed
for BD one can explore the potential for
interactions of BD with other chemicals
in the workplace, the environment, or
through certain dietary influences.
Model predictions of the results of such
interactions then form the basis for
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Figure 2. Physiological model predictions for the
pmoles BD (A) or pmoles styrene (B) metabolized by
rats exposed to various combinations of BD and
styrene assuming a simple competitive inhibition.
Bars represent model predictions of the amount of
each chemical metabolized both during and after 8-hr
simulated inhalation exposures to each of the combi-
nations of BD and styrene.
hypothesis that can be tested experimen-
tally. Three types ofsituations were sim-
ulated representing potential industrial,
environmental, and lifestyle exposure
scenarios.
Styrene-BD mixtures are often encoun-
tered in the workplace where both ofthese
monomers are used in the production of
synthetic rubber. Styrene, unlike BD, is
highly soluble in tissues, especially lipid
rich tissues. Oxidation ofstyrene to styrene
oxide occurs by cytochrome P4502E1
(30), the same P450 isozyme responsible
for oxidation of BD to BMO (21). Thus,
we hypothesized that the interaction
between these two chemicals could be
described within a physiological model as a
strictly competitive inhibition of each
chemical on the metabolism of the other.
Using published physiological models for
both styrene (24) and competitive inhibi-
tion [Ki = Kin; (31)], as well as the dosime-
try model for BD described above, we
simulated the amount of BD or styrene
metabolized both during and after inhala-
tion ofmixtures ofBD and styrene (Figure
2A,B). Thus, model predictions for the
total amount of BD or styrene metabo-
lized was used as a predictor of the extent
of inhibition. Under the conditions of
these simulations (i.e., strictly competitive
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inhibition) coexposure to styre:
the total amount of BD metab
not proportionally to the exposu
tration. In contrast, simulations
that BD is not an effective in
styrene even though the Km pat
the two chemicals are similar. )
dosimetry model, this is prima]
the low solubility ofBD in tissue
BD and benzene are both r
highly toxic environmental I
resulting from the combustive c
tive emmissions of automobilee
these two chemicals are subs
cytochrome P4502E1 (21,30), t
tion between these two chemica
modeled as competitive inhibi
physiological model of Medir
(32) was used to simulate bet
interactions. Similar to styrenc
model simulations predicted th;
was a more effective inhibit
metabolism than was BD of
metabolism (Figure 3A,B). Agai
ofthe low solubility ofBD, prec
centrations of this chemical in
never reached high enough to si
inhibit benzene metabolism.
The final simulation was th
ethanol induction ofcytochrom(
on the metabolism ofBD; in viv
known that ethanol is an inducer of
-100 P4502E1 (33). We simulated the inductive
effect ofethanol as a 2-fold increase in the
Vmax for BD oxidation. The simulations
50 assumed an 8-hr exposure to 10, 100, or
25 1000 ppm BD, and the total amount of
BD metabolized during and after exposure
t Mo was predicted. The results of the simula- ppmenen tions indicated that for 10, 100, or 1000
ppm BD, metabolism increased 113, 115,
and 158% of control, suggesting that
ethanol induction would not have a sub-
300 stantial effect on BD metabolism at con-
centrations relevant to human exposure.
-200 This marginal effect ofa 2-fold increase in
the maximal rate of BD metabolism pre-
100 dicted by the model is due to the fact that
at low inhaled concentrations of BD, BD
metabolism is probably blood flow-limited 100 and not enzyme capacity-limited. Thus, ppmBuadine model simulations predicted sufficient
enzyme at low BD concentrations to
tions for the metabolize all the BD presented to the liver etaboliDed by by the blood; increasing the capacity for
ibitiond Bars BD oxidation does not increase the total iount of each BD metabolized. However, at higher BD
ter 8-hr simu- concentrations, when metabolism begins to
combinations become saturated, increasing enzyme
capacity does increase the total amount of
BD metabolized.
ne reduces Discussion
olized but An understanding of the mechanisms by
ire concen- which BD induces tumors in rats and mice
suggested is essential for extrapolating to humans, a
thibitor of species for which BD carcinogenic potency
rameters of is at present unknown. This becomes par-
Within the ticularly important for assessing the effects
rily due to of chemical interactions with BD resulting
s. from environmental, industrial, and dietary
*egarded as exposures. It is likely that one ofthe critical
pollutants biochemical determinants of BD-induced
)r evapora- carcinogenicity is the extent to which BD is
s. Because activated to epoxide metabolites that can
strates for react with DNA to ultimately induce muta-
:he interac- tions. The induction ofmutations in tissues
ds also was ofa transgenic mouse is a novel approach to
ition. The determine in vivo mutation induction fol-
asky et al. lowing exposure to carcinogens. The induc-
nzene-BD tion ofmutations can be studied within the
e and BD, context ofthe endogenous pharmacokinetic
at benzene and biotransformation processes that deter-
tor of BD mine the tissue levels ofreactive metabolites
f benzene that can interact with and alter the cellular
in, because DNA in various tissues.
dicted con- Exposure of the MM strain of trans-
liver tissue genic mouse to 625 ppm of BD for five
ignificantly consecutive days (6 hr/day) followed by a
14-day expression period did not result in
Le effect of significant mutagenicity in liver and bone
e P4502E1 marrow. However, significant mutagenicity
Jo. It is well was observed in the lung, a target organ for
the carcinogenic effect of BD in B6C3F1
mice at 6.25 ppm. Specific mutation ofthe
K-ras oncogene has also been detected in
lung adenocarcinomas in BD-exposed mice
(10). Since there are no carcinogenicity
data in the MM strain of mouse exist for
the B6C3F1 mouse, it is difficult at present
to relate the relatively small increases in
mutagenicity observed in the present stud-
ies to another biological end point (e.g.,
tumor formation). Studies in this labora-
tory are in progress to evaluate the muta-
genicity of BD using a B6C3F1 mouse
mutation system(34).
Studies on the biotransformation ofBD
by MM liver microsomes indicate that MM
enzymes catalyze the conversion of BD to
BMO and hydrolysis of BMO (28). A
comparison ofthe initial rates (Vm,/AXl) of
BD metabolism to BMO and BMO
hydrolysis between MM and B6C3F1
mouse liver microsomes indicates that there
are also mouse strain differences in BD
metabolism. The ratio of Vma,x/Km for BD
to BMO and BMO hydrolysis in MM liver
microsomes was 225:1, while the ratio in
B6C3F1 mouse liver microsomes is 360:1
(28). The lack of mutagenicity of BD in
the liver ofthe MM may be due to an inef-
fective concentration of BMO in the liver.
Detailed parallel studies on the biotransfor-
mation of BD, in vitro and in vivo, in
B6C3F1 and MM are required to establish
the role ofBD bioactivation/detoxication in
mediating the genotoxic effects ofBD.
The data presented in this paper reveal
that there are significant species differences
in the Vmax observed for BD oxidation to
BMO. For example, B6C3F1 mouse liver
microsomes displayed a capacity for BD
oxidation exceeding that seen in either
human or rat liver. This was evidenced by a
comparison ofboth the maximum velocity
for the reaction, Vmax, and VmXIR/, Two
putative detoxication enzymic reactions can
occur with BMO: hydrolysis by epoxide
hydrolase and conjugation with GSH by
glutathione transferase. The results from
our studies reveal that liver tissues from all
species can detoxify BMO by both path-
ways. In general, human liver microsomes
hydrolyzed BMO at greater rates than
either rats or mice, as evidenced by the
higher Vmax and Vmax/Km. While there
was a considerable range of epoxide
hydrolase activities in liver microsomes
of the three human samples investigated
(Vmax=9 to 58 nmole/and mg protein/min),
values for the human samples were at least
2-fold greater than the Vm,,x for rats and
mice. The value reported by Kreuzer et al.
(35) for epoxide hydrolase-catalyzed
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hydrolysis of BMO by microsomes from a
single human liver sample (Vmax = 14
nmol/mg protein/min) falls within the
range of values for Vmax in human liver
microsomes reported in this paper. Values
for Vmax/Km reported by Kreuzer et al.
(35) for rodents and the one human liver
sample were similar to the values reported
in this paper. For all species, apparent Km
parameters for hydrolysis and GSH conju-
gation were significantly greater than for
BD oxidation and, in the case of mice,
BMO oxidation.
The three examples ofsimulations with
BD (i.e., BD-styrene, BD-benzene,
BD-ethanol) suggest two general impor-
tant points regarding chemical interactions.
The first relates to extrapolations from high
to low doses. Due to the saturable enzyme
systems that biotransform most toxic
organic chemicals, one cannot assume that
the inhibition effects demonstrated at high
exposure concentrations will be propor-
tional, or even significant, at low exposure
concentrations. Second, patterns ofenzyme
induction determined in vitro may not
exhibit the same magnitude ofeffect in the
intact animal. Delivery of the chemical to
the site of enzyme-chemical interaction
may be, in some cases, the rate-limiting
factor, rather than the quantity of the
enzyme present.
The simulations regarding the potential
interactions of styrene exposures on BD
metabolism and vice versa used a strictly
competitive inhibition model and suggested
that styrene would be an effective inhibitor
of BD metabolism but that BD would not
be an effective inhibitor ofstyrene metabo-
lism. A recent publication supports these
predictions. For example, Laib et al. (36)
reported that for Sprague-Dawley rats coex-
posed to styrene and BD, stryene decreased
the rate of metabolism of BD significantly,
but BD had no effect on the metabolism of
styrene. Additionally, these authors deter-
mined that the Ki for styrene in their sys-
tem was much lower than its apparent
Michaelis-Menten constant, suggesting that
the interaction between BD and styrene
might be more complex than the simple
competitive inhibition description used in
our model simulations.
The development of quantitative link-
ages between exposure and response, which
are based on biologically plausible mecha-
nisms of action at exposure levels that are
likely to be encountered by people, will sig-
nificantly improve the risk assessments for
human exposures to DNA-reactive chemi-
cals The present study was initiated to
begin to establish in vivo linkages between
exposure to BD, internal dose, and a bio-
logical response (mutation). The induction
of mutations is a determinant of BD-
induced carcinogenicity. Although the pre-
sent studies did not investigate the
carcinogenicity of BD in MM, the induc-
tion ofmutations in a transgene integrated
into the genome of the MM represents an
initial step towards establishing dose-
response relationships for molecular events
(mutation) that are part ofthe carcinogenic
process. These relationships need to be
established with endogenous genes that are
known to be involved in the carcinogenic
process (e.g., oncogenes and tumor supres-
sor genes). The in vitro metabolic constants
from these studies can be incorporated into
physiological models that can simulate in
vivo behavior and the models can be used
to predict blood and tissue concentrations
of BD and BMO. Experiments using
whole animals can then be used to verify
model predictions based on in vitro-derived
rates. These models are critical for predict-
ing epoxide metabolite concentrations in
tissues from exposures to chemical mixtures
containing BD.
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